Vonoprazan Versus Tegoprazan-Amoxicillin Dual Therapy for Treatment-Naïve Patients With Helicobacter pylori Infection: A Prospective, Multicenter, Open-Label, Randomized Controlled Study - PubMed
5 hours ago
- #clinical trial
- #Helicobacter pylori
- #dual therapy
- The study compared vonoprazan-amoxicillin (VA) and tegoprazan-amoxicillin (TA) dual therapies for Helicobacter pylori in treatment-naïve patients.
- VA therapy showed significantly higher eradication rates than TA in all analyses (ITT: 89.3% vs. 76.1%, p<0.001).
- Both therapies had comparable overall adverse event rates, but TA had fewer gastrointestinal adverse events (9.3% vs. 14.4%, p=0.048).
- Patient compliance was excellent and similar in both groups (over 94%).
- The authors concluded that VA dual therapy is effective and safe, while TA dosing may need optimization to improve eradication.